Zacks Investment Research upgraded Marinus Pharmaceuticals Inc (NASDAQ:MRNS) to Hold in a report released today.
- Updated: September 17, 2016
Zacks Investment Research has upgraded Marinus Pharmaceuticals Inc(NASDAQ:MRNS) to Hold in a report released on Friday August 19 2016.
On 8/10/2016, Jefferies reported on Marinus Pharmaceuticals Inc(NASDAQ:MRNS) raised the target price from $2.50 to $3.00. At the time, this suggested an upside of 1.07%.
Just yesterday Marinus Pharmaceuticals Inc (NASDAQ:MRNS) traded 3.05% higher at $1.68. The company’s 50-day average is $1.58 and its two hundred day average is $3.56. The last stock close is down 52.54% from the 200-day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. Trading volume was was down over the average, with 306,462 shares of MRNS changing hands under the typical 836,811 shares..
See Graphic Below:
With a total market value of $0.0, Marinus Pharmaceuticals Inc has a price-earnings of 0 with a one-year low of $1.19 and a one-year high of $13.78.
A total of 5 analysts have issued a ratings update on the company. Three firms rate the stock a strong buy, two firms rate the company a buy, 0 analysts rate the stock a hold, 0 rate the company to underperform, and lastly 0 brokeragesrate the stock as sell with an average target price of $16.20
General Company Details For Marinus Pharmaceuticals Inc (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and and PCDH19 pediatric epilepsy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.